Nelson Hydrochloride Ranitidine Tablet 150mg (Ranitidine Hydrochloride)
Ranitidine Hydrochloride 168mg
Tablet · Prescription medication
Korea Nelson Pharmaceutical Co., Ltd.
MFDS item code 199501734 · Notified 1995.10.06
This product's status changed to Expired on 2025.04.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of acid-related disorders (e.g., ulcers, gastroesophageal reflux disease), improvement of the gastric mucosa, and prevention of Mendelson syndrome
This medication is used for ulcers in the stomach and duodenum, Zollinger-Ellison syndrome, and gastroesophageal reflux disease, and is also effective in preventing Mendelson's syndrome that can occur during anesthesia before surgery. It helps treat gastric ulcers caused by non-steroidal anti-inflammatory drugs (NSAIDs). It improves damage such as erosion, bleeding, redness, and swelling of the gastric mucosa during acute exacerbations of acute and chronic gastritis as well as upper gastrointestinal bleeding. Additionally, it alleviates symptoms of gastric acid excess, heartburn, and reflux, thereby overall helping digestive health. This medication is used to improve gastrointestinal health and treat various gastric-related diseases.
Adults As ranitidine, 150 mg orally twice daily, in the morning and at bedtime. Gastric and duodenal ulcers: Administer this drug orally at 150 mg twice daily or 300 mg once daily at bedtime. A higher healing rate may be achieved, particularly in patients with duodenal ulcers, by administering 300 mg twice daily, in the morning and at bedtime. The same dosage applies to combination therapy for ulcers caused by nonsteroidal anti-inflammatory drugs or for the prevention of gastric and duodenal ulcers during long-term use of nonsteroidal anti-inflammatory drugs. Healing usually occurs within 4 weeks; conditions caused by nonsteroidal anti-inflammatory drugs usually heal within 8 weeks, although healing may occasionally take longer in some patients. For patients with recurrent ulcers who responded well to short-term treatment with this drug, administer 150 mg once daily at bedtime as maintenance therapy. Gastroesophageal reflux disease: Administer this drug at 150 mg twice daily for 8 weeks or 300 mg once daily at bedtime. The dose may be increased to 150 mg four times daily in patients with severe gastroesophageal reflux disease. Zollinger-Ellison syndrome: Initiate treatment with this drug at an initial dose of 150 mg three times daily; the dose may be increased as needed. For severe disease, up to 6 g per day may be administered as directed by a physician. For upper gastrointestinal bleeding due to peptic ulcers, acute stress ulcers, or acute gastric mucosal lesions, treatment is usually initiated with an injectable formulation. Once oral administration is possible, switch to oral treatment with this drug at 150 mg twice daily. Pre-anesthetic medication (prevention of Mendelson syndrome): Administer 150 mg of this drug 2 hours before induction of anesthesia. It is also preferable to administer 150 mg on the evening before surgery. Improvement of gastric mucosal lesions (erosions, bleeding, redness, and edema) in the following conditions: acute gastritis and acute exacerbation of chronic gastritis: Administer this drug at 150 mg once daily at bedtime. Hyperacidity, heartburn, acid regurgitation: In patients aged 12 years and older, administer this drug orally at 75 mg twice daily (oral solution only). Patients with renal impairment: In patients with severe renal impairment and creatinine clearance of 50 mL/min or less, administer 150 mg once daily at bedtime. Depending on the patient's condition, the dosing interval may be extended to 12 hours or longer. Hemodialysis reduces the plasma concentration of the drug; adjust the dosing schedule immediately after hemodialysis. Adjust the dose appropriately according to age and symptoms.
Ages 8–18 years: 150 mg (2 mg/kg) per dose may be administered up to twice daily.
This medication should not be used by patients who have had allergic reactions to its ingredients or have a history of acute porphyria. Patients with poor kidney function may need to reduce the dosage or increase the dosing interval as this medication can remain in the body for a longer time. Patients with impaired liver function should also use it with caution. Patients with a history of drug allergies or elderly patients, as well as those taking non-steroidal anti-inflammatory drugs (NSAIDs), should be monitored closely while using this drug. This medication may mask symptoms of stomach cancer, so those with gastric ulcers or any newly developed indigestion symptoms in individuals aged middle-aged and above should confirm malignancy before use. Patients with duodenal ulcers infected with Helicobacter pylori require eradication therapy for the bacteria. This medication may rarely cause severe allergic reactions, blood abnormalities, liver dysfunction, cardiac rhythm problems, gastrointestinal symptoms, neurological abnormalities, myalgia, skin rashes, etc., and should be stopped immediately if any abnormal symptoms occur and consult a doctor. During treatment, the course of the disease should be closely observed and used only as necessary; if ineffective, alternative treatment should be considered. Elderly individuals, patients with chronic lung diseases, diabetes, or weakened immunity may be at increased risk of pneumonia, so caution is advised. If dizziness or drowsiness occurs following administration of this medication, avoid driving or operating dangerous machinery. When used with other medications, absorption or metabolism may be affected, so inform your doctor or pharmacist, and dosage adjustments may be necessary. Pregnant or breastfeeding women should use this drug cautiously, as its safety has not been established and it should only be used when necessary. In children, safety has not been sufficiently confirmed, so caution is required. In cases of overdose, while serious problems are rare, treatments such as vomiting or gastric lavage may be necessary, and in severe cases, dialysis may be needed. Keep this medication out of reach of children and do not transfer it to other containers for safety. Due to this medication's reduction in gastric acid secretion, prolonged use may lead to an increase in gastric bacteria, necessitating caution with long-term use. It is advisable to have an eye health check during long-term administration.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a dark container that does not allow light in. Moreover, it is best stored at room temperature between 1 to 30 degrees Celsius. Proper storage ensures the effectiveness and safety of the medication.
White round film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ranitidine Hydrochloride 168mg
Tablet · Prescription medication
Korea Nelson Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 168mg
Prescription medication
Ildong Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 168mg
Tablet · Prescription medication
Hana Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 56mg
Prescription medication
Ildong Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 336mg
Prescription medication
Ildong Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 168mg
Tablet · Prescription medication
Hanin Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 112mg
Solution · Prescription medication
Hanin Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 56mg
Solution · Prescription medication
Hanin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.